UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active ...

The "atopic march" describes the age-related progression of allergic diseases, presenting as the sequential onset of atopic ...

The use of interleukin (IL)-23 inhibitors plays an important role in treating patients with psoriasis, as well as in treating ...

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous ...

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often ...

New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the ...

Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological ...

The hidradenitis suppurativa market is poised for strong growth, driven by increasing disease awareness, earlier diagnosis, and expanding treatment access. Advances in biologic and targeted therapies, ...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan. LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinica ...

Objectives Patients with primary Sjögren’s disease (SjD) have an increased risk of B cell lymphoma. The aim of this study was ...

Reviewers viewed the targeting of TFAM as innovative and the study's conclusions as potentially important (especially the effects on inflammation). However, the lack of evidence for a direct effect of ...

DelveInsight's Emphysema Market Insights report includes a comprehensive understanding of current treatment practices, emphysema emerging drugs, market share of individual therapies, and current and ...